Animals can sense internal nutrients, such as amino acids/proteins, and are able to modify their developmental programs in accordance with their nutrient status. In the fruit fly, , amino acid/protein is sensed by the fat body, an insect adipose tissue, through a nutrient sensor, target of rapamycin (TOR) complex 1 (TORC1). TORC1 promotes the secretion of various peptide hormones from the fat body in an amino acid/protein-dependent manner. Fat-body-derived peptide hormones stimulate the release of insulin-like peptides, which are essential growth-promoting anabolic hormones, from neuroendocrine cells called insulin-producing cells (IPCs). Although the importance of TORC1 and the fat body-IPC axis has been elucidated, the mechanism by which TORC1 regulates the expression of insulinotropic signal peptides remains unclear. Here, we show that an evolutionarily conserved molecular chaperone, heat shock protein 90 (Hsp90), promotes the expression of insulinotropic signal peptides. Fat-body-selective knockdown caused the transcriptional downregulation of insulinotropic signal peptides. IPC activity and systemic growth were also impaired in fat-body-selective knockdown animals. Furthermore, expression depended on protein/amino acid availability and TORC1 signaling. These results strongly suggest that serves as a nutrient-responsive gene that upregulates the fat body-IPC axis and systemic growth. We propose that is induced in a nutrient-dependent manner to support anabolic metabolism during the juvenile growth period.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258382PMC
http://dx.doi.org/10.3389/fphys.2021.690564DOI Listing

Publication Analysis

Top Keywords

insulinotropic signal
12
signal peptides
12
molecular chaperone
8
fat body
8
peptide hormones
8
fat body-ipc
8
body-ipc axis
8
expression insulinotropic
8
fat-body-selective knockdown
8
systemic growth
8

Similar Publications

The other side of the incretin story: GIPR signaling in energy homeostasis.

Cell Metab

January 2025

Departments of Cellular & Molecular Physiology and Internal Medicine (Endocrinology), Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address:

Incretin receptor agonists have been effective in combatting obesity and diabetes. While the body of knowledge regarding the signaling mechanisms of glucagon-like peptide 1 (GLP-1) receptor agonists is ever-growing, glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists are less understood. The previewed papers offer insight into the impact of adipose GIPR on energy and weight homeostasis.

View Article and Find Full Text PDF

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are gut-derived peptide hormones that potentiate glucose-dependent insulin secretion. The clinical development of GIP receptor (GIPR)-GLP-1 receptor (GLP-1R) multi-agonists exemplified by tirzepatide and emerging GIPR antagonist-GLP-1R agonist therapeutics such as maritide is increasing interest in the extra-pancreatic actions of incretin therapies. Both GLP-1 and GIP modulate inflammation, with GLP-1 also acting locally to alleviate gut inflammation in part through anti-inflammatory actions on GLP-1R+ intestinal intraepithelial lymphocytes.

View Article and Find Full Text PDF

Dexmedetomidine suppresses glucose-stimulated insulin secretion in pancreatic β-cells.

FEBS Open Bio

December 2024

Department of Cell Physiology, Institute of Biomedical Science, Kansai Medical University, Hirakata, Osaka, Japan.

Article Synopsis
  • Proper glycemic control is important in critical care settings, as it can impact patient outcomes and is influenced by factors such as insulin secretion and glucose metabolism.
  • Various perioperative drugs, particularly dexmedetomidine (DEX), are shown to suppress glucose-stimulated insulin secretion, but the mechanisms remain unclear.
  • Research using pancreatic cell lines and primary cells indicates that DEX reduces insulin secretion without significantly altering other cellular processes, suggesting that it affects insulin signaling pathways and exocytosis mechanisms.
View Article and Find Full Text PDF

GLP-1RA based therapies in the young and old.

Curr Opin Endocrinol Diabetes Obes

February 2025

Austin Health, Continuing Care.

Purpose Of Review: Obesity is recognized as a "gateway" chronic, progressive disease of dysfunctional adipocytes. Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without glucose-dependent insulinotropic polypeptide (GIP), have demonstrated clinically significant weight loss and health gains in adults, hence interest in using them in younger and older people. Therefore, reviewing the role of GLP1BTs in these populations is pertinent and timely.

View Article and Find Full Text PDF

Like humans, cats have a strong relationship between decreasing insulin sensitivity and the development of diabetes with obesity. However, the underlying molecular mechanisms of impaired insulin secretion and signaling in cats remain largely unknown. A total of 54 client-owned nondiabetic lean ( = 15), overweight ( = 15), and diabetic ( = 24) cats were included in the study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!